Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the open-label period was to evaluate the...
Gespeichert in:
| Veröffentlicht in: | The Lancet. Haematology Jg. 9; H. 9; S. e648 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
01.09.2022
|
| ISSN: | 2352-3026, 2352-3026 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the open-label period was to evaluate the long-term efficacy and safety of pegcetacoplan through to 48 weeks.BACKGROUNDIn the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the open-label period was to evaluate the long-term efficacy and safety of pegcetacoplan through to 48 weeks.PEGASUS was a phase 3, randomised, open-label, active-comparator controlled trial conducted in 44 centres in Australia, Belgium, Canada, France, Germany, Japan, Russia, South Korea, Spain, the UK, and the USA. Eligible participants were aged 18 years or older, had paroxysmal nocturnal haemoglobinuria, and had a haemoglobin concentration of less than 10·50 g/dL after 3 months or longer of stable eculizumab treatment. After a 4-week run-in with eculizumab plus pegcetacoplan, patients were randomly assigned (1:1) by interactive response technology to pegcetacoplan (1080 mg subcutaneously twice weekly) or eculizumab (according to their regimen at enrolment) for 16 weeks and could continue to the open-label period (32 weeks of pegcetacoplan monotherapy [pegcetacoplan-to-pegcetacoplan] or 28 weeks of pegcetacoplan monotherapy [eculizumab-to-pegcetacoplan]). Randomisation was stratified by platelet count and number of previous blood transfusions. The primary endpoint was change from baseline in haemoglobin at week 16, which has previously been reported. The outcomes of the open-label period (week 16 to week 48) are reported here. At 48 weeks, efficacy (including mean haemoglobin concentration and quality of life measured on the Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue scale) was assessed in the intention-to-treat population and safety was assessed per protocol. This trial was registered with ClinicalTrials.gov, NCT03500549, and has been completed.METHODSPEGASUS was a phase 3, randomised, open-label, active-comparator controlled trial conducted in 44 centres in Australia, Belgium, Canada, France, Germany, Japan, Russia, South Korea, Spain, the UK, and the USA. Eligible participants were aged 18 years or older, had paroxysmal nocturnal haemoglobinuria, and had a haemoglobin concentration of less than 10·50 g/dL after 3 months or longer of stable eculizumab treatment. After a 4-week run-in with eculizumab plus pegcetacoplan, patients were randomly assigned (1:1) by interactive response technology to pegcetacoplan (1080 mg subcutaneously twice weekly) or eculizumab (according to their regimen at enrolment) for 16 weeks and could continue to the open-label period (32 weeks of pegcetacoplan monotherapy [pegcetacoplan-to-pegcetacoplan] or 28 weeks of pegcetacoplan monotherapy [eculizumab-to-pegcetacoplan]). Randomisation was stratified by platelet count and number of previous blood transfusions. The primary endpoint was change from baseline in haemoglobin at week 16, which has previously been reported. The outcomes of the open-label period (week 16 to week 48) are reported here. At 48 weeks, efficacy (including mean haemoglobin concentration and quality of life measured on the Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue scale) was assessed in the intention-to-treat population and safety was assessed per protocol. This trial was registered with ClinicalTrials.gov, NCT03500549, and has been completed.Between June 14, 2018, and Nov 14, 2019, 80 patients were randomly assigned to receive treatment with pegcetacoplan (41 patients) or eculizumab (39 patients). Most participants were women (49 [61%]) and 31 (39%) were men; 12 (15%) were Asian, two (3%) were Black, 49 (61%) were White, and 17 (21%) were another race or did not report their race. The open-label period had 77 participants (38 pegcetacoplan-to-pegcetacoplan, 39 eculizumab-to-pegcetacoplan). Patients in the pegcetacoplan-to-pegcetacoplan group maintained high mean haemoglobin concentrations between 16 weeks (11·54 g/dL [SD 1·96]) and 48 weeks (11·30 g/dL [1·77]; p=0·14). Patients in the eculizumab-to-pegcetacoplan group had significantly greater mean haemoglobin concentrations at 48 weeks (11·57 g/dL [2·21]) versus 16 weeks (8·58 g/dL [0·96]; p<0·0001). Clinically meaningful improvements in FACIT-Fatigue scores were observed at 48 weeks, with a mean change from baseline for all patients receiving pegcetacoplan monotherapy of 9·89 points (SD 9·63), for patients in the pegcetacoplan-to-pegcetacoplan group mean 10·14 points (9·06), and for patients in the eculizumab-to-pegcetacoplan group mean 9·62 points (10·34). During the entire study period, 13 (16%) of 80 patients discontinued treatment (three [7%] of 41 through to week 16 due to breakthrough haemolysis, and ten [13%] of 77 due to severe treatment-emergent adverse events) and 18 patients (eight pegcetacoplan-to-pegcetacoplan, ten eculizumab-to-pegcetacoplan) had at least one serious treatment-emergent adverse event during the open-label period, four were considered to be related to pegcetacoplan treatment. The most common treatment-emergent adverse events (in ≥10% patients) among both pegcetacoplan-treated groups during the open-label period were injection site reactions (in 20 [26%] of 77 patients), haemolysis (15 [19%]), nasopharyngitis (12 [16%]), and diarrhoea (ten [13%]). No treatment-related deaths occurred throughout the duration of the study.FINDINGSBetween June 14, 2018, and Nov 14, 2019, 80 patients were randomly assigned to receive treatment with pegcetacoplan (41 patients) or eculizumab (39 patients). Most participants were women (49 [61%]) and 31 (39%) were men; 12 (15%) were Asian, two (3%) were Black, 49 (61%) were White, and 17 (21%) were another race or did not report their race. The open-label period had 77 participants (38 pegcetacoplan-to-pegcetacoplan, 39 eculizumab-to-pegcetacoplan). Patients in the pegcetacoplan-to-pegcetacoplan group maintained high mean haemoglobin concentrations between 16 weeks (11·54 g/dL [SD 1·96]) and 48 weeks (11·30 g/dL [1·77]; p=0·14). Patients in the eculizumab-to-pegcetacoplan group had significantly greater mean haemoglobin concentrations at 48 weeks (11·57 g/dL [2·21]) versus 16 weeks (8·58 g/dL [0·96]; p<0·0001). Clinically meaningful improvements in FACIT-Fatigue scores were observed at 48 weeks, with a mean change from baseline for all patients receiving pegcetacoplan monotherapy of 9·89 points (SD 9·63), for patients in the pegcetacoplan-to-pegcetacoplan group mean 10·14 points (9·06), and for patients in the eculizumab-to-pegcetacoplan group mean 9·62 points (10·34). During the entire study period, 13 (16%) of 80 patients discontinued treatment (three [7%] of 41 through to week 16 due to breakthrough haemolysis, and ten [13%] of 77 due to severe treatment-emergent adverse events) and 18 patients (eight pegcetacoplan-to-pegcetacoplan, ten eculizumab-to-pegcetacoplan) had at least one serious treatment-emergent adverse event during the open-label period, four were considered to be related to pegcetacoplan treatment. The most common treatment-emergent adverse events (in ≥10% patients) among both pegcetacoplan-treated groups during the open-label period were injection site reactions (in 20 [26%] of 77 patients), haemolysis (15 [19%]), nasopharyngitis (12 [16%]), and diarrhoea (ten [13%]). No treatment-related deaths occurred throughout the duration of the study.The durability of improved haematological outcomes and favourable safety profile over 48 weeks of treatment suggests that pegcetacoplan has the potential to improve treatment benefit and alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria.INTERPRETATIONThe durability of improved haematological outcomes and favourable safety profile over 48 weeks of treatment suggests that pegcetacoplan has the potential to improve treatment benefit and alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria.Apellis Pharmaceuticals.FUNDINGApellis Pharmaceuticals. |
|---|---|
| AbstractList | In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the open-label period was to evaluate the long-term efficacy and safety of pegcetacoplan through to 48 weeks.BACKGROUNDIn the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the open-label period was to evaluate the long-term efficacy and safety of pegcetacoplan through to 48 weeks.PEGASUS was a phase 3, randomised, open-label, active-comparator controlled trial conducted in 44 centres in Australia, Belgium, Canada, France, Germany, Japan, Russia, South Korea, Spain, the UK, and the USA. Eligible participants were aged 18 years or older, had paroxysmal nocturnal haemoglobinuria, and had a haemoglobin concentration of less than 10·50 g/dL after 3 months or longer of stable eculizumab treatment. After a 4-week run-in with eculizumab plus pegcetacoplan, patients were randomly assigned (1:1) by interactive response technology to pegcetacoplan (1080 mg subcutaneously twice weekly) or eculizumab (according to their regimen at enrolment) for 16 weeks and could continue to the open-label period (32 weeks of pegcetacoplan monotherapy [pegcetacoplan-to-pegcetacoplan] or 28 weeks of pegcetacoplan monotherapy [eculizumab-to-pegcetacoplan]). Randomisation was stratified by platelet count and number of previous blood transfusions. The primary endpoint was change from baseline in haemoglobin at week 16, which has previously been reported. The outcomes of the open-label period (week 16 to week 48) are reported here. At 48 weeks, efficacy (including mean haemoglobin concentration and quality of life measured on the Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue scale) was assessed in the intention-to-treat population and safety was assessed per protocol. This trial was registered with ClinicalTrials.gov, NCT03500549, and has been completed.METHODSPEGASUS was a phase 3, randomised, open-label, active-comparator controlled trial conducted in 44 centres in Australia, Belgium, Canada, France, Germany, Japan, Russia, South Korea, Spain, the UK, and the USA. Eligible participants were aged 18 years or older, had paroxysmal nocturnal haemoglobinuria, and had a haemoglobin concentration of less than 10·50 g/dL after 3 months or longer of stable eculizumab treatment. After a 4-week run-in with eculizumab plus pegcetacoplan, patients were randomly assigned (1:1) by interactive response technology to pegcetacoplan (1080 mg subcutaneously twice weekly) or eculizumab (according to their regimen at enrolment) for 16 weeks and could continue to the open-label period (32 weeks of pegcetacoplan monotherapy [pegcetacoplan-to-pegcetacoplan] or 28 weeks of pegcetacoplan monotherapy [eculizumab-to-pegcetacoplan]). Randomisation was stratified by platelet count and number of previous blood transfusions. The primary endpoint was change from baseline in haemoglobin at week 16, which has previously been reported. The outcomes of the open-label period (week 16 to week 48) are reported here. At 48 weeks, efficacy (including mean haemoglobin concentration and quality of life measured on the Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue scale) was assessed in the intention-to-treat population and safety was assessed per protocol. This trial was registered with ClinicalTrials.gov, NCT03500549, and has been completed.Between June 14, 2018, and Nov 14, 2019, 80 patients were randomly assigned to receive treatment with pegcetacoplan (41 patients) or eculizumab (39 patients). Most participants were women (49 [61%]) and 31 (39%) were men; 12 (15%) were Asian, two (3%) were Black, 49 (61%) were White, and 17 (21%) were another race or did not report their race. The open-label period had 77 participants (38 pegcetacoplan-to-pegcetacoplan, 39 eculizumab-to-pegcetacoplan). Patients in the pegcetacoplan-to-pegcetacoplan group maintained high mean haemoglobin concentrations between 16 weeks (11·54 g/dL [SD 1·96]) and 48 weeks (11·30 g/dL [1·77]; p=0·14). Patients in the eculizumab-to-pegcetacoplan group had significantly greater mean haemoglobin concentrations at 48 weeks (11·57 g/dL [2·21]) versus 16 weeks (8·58 g/dL [0·96]; p<0·0001). Clinically meaningful improvements in FACIT-Fatigue scores were observed at 48 weeks, with a mean change from baseline for all patients receiving pegcetacoplan monotherapy of 9·89 points (SD 9·63), for patients in the pegcetacoplan-to-pegcetacoplan group mean 10·14 points (9·06), and for patients in the eculizumab-to-pegcetacoplan group mean 9·62 points (10·34). During the entire study period, 13 (16%) of 80 patients discontinued treatment (three [7%] of 41 through to week 16 due to breakthrough haemolysis, and ten [13%] of 77 due to severe treatment-emergent adverse events) and 18 patients (eight pegcetacoplan-to-pegcetacoplan, ten eculizumab-to-pegcetacoplan) had at least one serious treatment-emergent adverse event during the open-label period, four were considered to be related to pegcetacoplan treatment. The most common treatment-emergent adverse events (in ≥10% patients) among both pegcetacoplan-treated groups during the open-label period were injection site reactions (in 20 [26%] of 77 patients), haemolysis (15 [19%]), nasopharyngitis (12 [16%]), and diarrhoea (ten [13%]). No treatment-related deaths occurred throughout the duration of the study.FINDINGSBetween June 14, 2018, and Nov 14, 2019, 80 patients were randomly assigned to receive treatment with pegcetacoplan (41 patients) or eculizumab (39 patients). Most participants were women (49 [61%]) and 31 (39%) were men; 12 (15%) were Asian, two (3%) were Black, 49 (61%) were White, and 17 (21%) were another race or did not report their race. The open-label period had 77 participants (38 pegcetacoplan-to-pegcetacoplan, 39 eculizumab-to-pegcetacoplan). Patients in the pegcetacoplan-to-pegcetacoplan group maintained high mean haemoglobin concentrations between 16 weeks (11·54 g/dL [SD 1·96]) and 48 weeks (11·30 g/dL [1·77]; p=0·14). Patients in the eculizumab-to-pegcetacoplan group had significantly greater mean haemoglobin concentrations at 48 weeks (11·57 g/dL [2·21]) versus 16 weeks (8·58 g/dL [0·96]; p<0·0001). Clinically meaningful improvements in FACIT-Fatigue scores were observed at 48 weeks, with a mean change from baseline for all patients receiving pegcetacoplan monotherapy of 9·89 points (SD 9·63), for patients in the pegcetacoplan-to-pegcetacoplan group mean 10·14 points (9·06), and for patients in the eculizumab-to-pegcetacoplan group mean 9·62 points (10·34). During the entire study period, 13 (16%) of 80 patients discontinued treatment (three [7%] of 41 through to week 16 due to breakthrough haemolysis, and ten [13%] of 77 due to severe treatment-emergent adverse events) and 18 patients (eight pegcetacoplan-to-pegcetacoplan, ten eculizumab-to-pegcetacoplan) had at least one serious treatment-emergent adverse event during the open-label period, four were considered to be related to pegcetacoplan treatment. The most common treatment-emergent adverse events (in ≥10% patients) among both pegcetacoplan-treated groups during the open-label period were injection site reactions (in 20 [26%] of 77 patients), haemolysis (15 [19%]), nasopharyngitis (12 [16%]), and diarrhoea (ten [13%]). No treatment-related deaths occurred throughout the duration of the study.The durability of improved haematological outcomes and favourable safety profile over 48 weeks of treatment suggests that pegcetacoplan has the potential to improve treatment benefit and alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria.INTERPRETATIONThe durability of improved haematological outcomes and favourable safety profile over 48 weeks of treatment suggests that pegcetacoplan has the potential to improve treatment benefit and alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria.Apellis Pharmaceuticals.FUNDINGApellis Pharmaceuticals. |
| Author | Kiladjian, Jean-Jacques Höchsmann, Britta Risitano, Antonio M Szer, Jeff Usuki, Kensuke Panse, Jens Röth, Alexander Weitz, Ilene C Nishimori, Hisakazu de Castro, Carlos M Deschatelets, Pascal Griffin, Morag Ajayi, Temitayo Grossi, Federico Hillmen, Peter Francois, Cedric Al-Adhami, Mohammed de Latour, Régis Peffault |
| Author_xml | – sequence: 1 givenname: Régis Peffault surname: de Latour fullname: de Latour, Régis Peffault – sequence: 2 givenname: Jeff surname: Szer fullname: Szer, Jeff – sequence: 3 givenname: Ilene C surname: Weitz fullname: Weitz, Ilene C – sequence: 4 givenname: Alexander surname: Röth fullname: Röth, Alexander – sequence: 5 givenname: Britta surname: Höchsmann fullname: Höchsmann, Britta – sequence: 6 givenname: Jens surname: Panse fullname: Panse, Jens – sequence: 7 givenname: Kensuke surname: Usuki fullname: Usuki, Kensuke – sequence: 8 givenname: Morag surname: Griffin fullname: Griffin, Morag – sequence: 9 givenname: Jean-Jacques surname: Kiladjian fullname: Kiladjian, Jean-Jacques – sequence: 10 givenname: Carlos M surname: de Castro fullname: de Castro, Carlos M – sequence: 11 givenname: Hisakazu surname: Nishimori fullname: Nishimori, Hisakazu – sequence: 12 givenname: Temitayo surname: Ajayi fullname: Ajayi, Temitayo – sequence: 13 givenname: Mohammed surname: Al-Adhami fullname: Al-Adhami, Mohammed – sequence: 14 givenname: Pascal surname: Deschatelets fullname: Deschatelets, Pascal – sequence: 15 givenname: Cedric surname: Francois fullname: Francois, Cedric – sequence: 16 givenname: Federico surname: Grossi fullname: Grossi, Federico – sequence: 17 givenname: Antonio M surname: Risitano fullname: Risitano, Antonio M – sequence: 18 givenname: Peter surname: Hillmen fullname: Hillmen, Peter |
| BookMark | eNpNUNtO3DAUtCqQuH4C0nlcpHXrOHGy5g0hoEhIRVp4Rif2MZvi2CF2dmm_jY9rpFaoT3N5mBnNEdsLMRBjZ4X4Woii_raWpZK8FLJeSHkuhCwEL76ww0977z9-wE5T-imEKMqmVrU-ZB8P9GIoo4mDxwBbGtOUgMzku99Tjy10AQbMHYWcYNflzazG-P4r9eghRJOnMcxsg9THFx_bLkxjh7B4uL69XD-tzy-gWvEd0Su46H3c8WmA6ABhxGBj3yWyS4gDBe6xJb-EYYOJoFwCmtxtiZvYz42Y47gEE0Me5xiykOcWf8L2HfpEp__wmD3dXD9efef3P27vri7vuSm1yly6Co2lVeusbk3jpFK2WelGoEFLZWsro5SoVlo5skorUk5pU1pVOF1R08pjtvibO4zxbaKUn-fhhvz8GMUpPctG6KYSlajlH6wLftQ |
| CitedBy_id | crossref_primary_10_7759_cureus_81134 crossref_primary_10_1007_s00277_024_05699_8 crossref_primary_10_3390_ijms25179477 crossref_primary_10_1016_S2352_3026_25_00081_X crossref_primary_10_1182_blood_2024027600 crossref_primary_10_1182_bloodadvances_2024012672 crossref_primary_10_1016_S2352_3026_22_00241_1 crossref_primary_10_1159_000537696 crossref_primary_10_1056_NEJMc2404445 crossref_primary_10_3390_hematolrep16040065 crossref_primary_10_3390_jcm13061703 crossref_primary_10_1080_17512433_2024_2403638 crossref_primary_10_1007_s12325_023_02653_4 crossref_primary_10_1080_1750743X_2024_2433410 crossref_primary_10_1007_s12325_025_03310_8 crossref_primary_10_1007_s40268_024_00500_7 crossref_primary_10_1007_s00277_024_05858_x crossref_primary_10_1002_ajh_27242 crossref_primary_10_1055_s_0044_1795143 crossref_primary_10_3390_ijms25168591 crossref_primary_10_1007_s12325_023_02510_4 crossref_primary_10_1007_s15004_024_0559_4 crossref_primary_10_1371_journal_pone_0306407 crossref_primary_10_1080_03007995_2024_2354533 crossref_primary_10_1016_j_blre_2023_101158 crossref_primary_10_1002_ajh_26832 crossref_primary_10_1007_s12325_024_02827_8 crossref_primary_10_1182_blood_2024027574 crossref_primary_10_3390_ijms25168698 crossref_primary_10_1016_j_medp_2025_100070 crossref_primary_10_1007_s40265_022_01809_w crossref_primary_10_17650_1818_8346_2024_19_3_68_78 crossref_primary_10_3390_hematolrep15040060 crossref_primary_10_1016_j_rpth_2024_102416 crossref_primary_10_1007_s10238_025_01834_5 crossref_primary_10_1177_20406207231216080 crossref_primary_10_1016_S0140_6736_23_01524_6 crossref_primary_10_1159_000540474 crossref_primary_10_3389_fimmu_2025_1529184 crossref_primary_10_2147_JBM_S362220 crossref_primary_10_1093_ndt_gfae231 crossref_primary_10_1182_bloodadvances_2023011691 crossref_primary_10_3390_ijms26125902 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. |
| DBID | 7X8 |
| DOI | 10.1016/S2352-3026(22)00210-1 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2352-3026 |
| GroupedDBID | -RU .1- .FO 0R~ 1P~ 4.4 457 53G 7X8 AAEDT AAEDW AALRI AAMRU AAQFI AAQQT AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS EFKBS FDB HZ~ M41 O9- OC~ OO- Z5R |
| ID | FETCH-LOGICAL-c395t-2f4acde8bfd9bc7f255d78970acade3bd4c5504895fed595e5f59c3d51f94e7b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 52 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000876363200017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2352-3026 |
| IngestDate | Sun Sep 28 05:08:34 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c395t-2f4acde8bfd9bc7f255d78970acade3bd4c5504895fed595e5f59c3d51f94e7b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PQID | 2709740406 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2709740406 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | The Lancet. Haematology |
| PublicationYear | 2022 |
| SSID | ssj0001376569 |
| Score | 2.462106 |
| Snippet | In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | e648 |
| Title | Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial |
| URI | https://www.proquest.com/docview/2709740406 |
| Volume | 9 |
| WOSCitedRecordID | wos000876363200017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9QwFA7qivjiXbxzBB92YcJ20qZJfBGRXX3QZWAV5m3J5WR3cKYZt1MX_G3-OE9q1nnwRfCxpYSWfP3ONedj7FWrfGudrHhlUfFGt5Ib7SxHikUoIIpK4jgy_6M6OtLzuZmVhFtf2iovOXEk6pB8zpHvC1WR60uQa9-sv_GsGpWrq0VC4yrbqcmVyahWc73NsdDfI0dVO0F-Bq8p3tge4tk__nNzV4i9Mfjh078oebQzh7f_9w3vsFvFw4S3vyFxl13B7h678anU0O-znzM89bghJlwvbQe5LWPoIWvkLn4MK-tg0UGZttpDTtPSVe516Ve0apdyySGvf2ZxlfI4kUU3EIhhd3bwnjj6eO81NJpfIH6FSBhLF3xYQ4pggaxiSAQrDBPIol2cAIjLCazPyJJCPQE7ci_3ZSB5Op9A6aRfYoBRX-QB-3J48PndB140HLivjdxwERvrA2oXg3FeRYpggtJGVTa3_9cuNJ5ipEYbGTFII1FGaXwd5DSaBpUTD9m1LnX4iIGfhmhVPcU6uMYra6vMzdEpLVsUbXjMXl7uywl9TC582A7T0J9sd-bJPzzzlN0U-YwDwUHoZ2wnEg_gc3bdf98s-vMXI8R-AfSe3pU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pegcetacoplan+versus+eculizumab+in+patients+with+paroxysmal+nocturnal+haemoglobinuria+%28PEGASUS%29%3A+48-week+follow-up+of+a+randomised%2C+open-label%2C+phase+3%2C+active-comparator%2C+controlled+trial&rft.jtitle=The+Lancet.+Haematology&rft.au=de+Latour%2C+R%C3%A9gis+Peffault&rft.au=Szer%2C+Jeff&rft.au=Weitz%2C+Ilene+C&rft.au=R%C3%B6th%2C+Alexander&rft.date=2022-09-01&rft.issn=2352-3026&rft.eissn=2352-3026&rft.volume=9&rft.issue=9&rft.spage=e648&rft_id=info:doi/10.1016%2FS2352-3026%2822%2900210-1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3026&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3026&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3026&client=summon |